The enrollment update is incrementally positive for trial progress but provides no efficacy data or commercial de-risking. Given SXTP's micro-cap status ($4M market cap) and negative historical return patterns on prior analyses, the stock may react modestly to the ahead-of-schedule milestone, but the binary risk of interim results later in 2026 dominates.
Price Chart
Executive Summary
60 Degrees Pharmaceuticals announced enrollment of the first patient of the 2026 tick season in a Phase 2 clinical trial (NCT06207370) evaluating tafenoquine for babesiosis. Enrollment is tracking ahead of schedule, with minimum enrollment for an interim analysis potentially achieved as early as July 2026. The press release is a clinical update with no new financial data or efficacy results.
Key Facts
- First patient of the 2026 tick season enrolled in randomized, double-blind, placebo-controlled trial (NCT06207370) for tafenoquine in babesiosis.
- Minimum enrollment of 24 patients for interim analysis expected as soon as early July 2026, approximately one month ahead of schedule.
- Interim analysis date to be announced approximately 50 days after enrollment completion.
- Tafenoquine is already FDA-approved for malaria prophylaxis as ARAKODA, but not approved for babesiosis.
Financial Impact
No financial figures disclosed; the filing is a clinical enrollment update with no revenue, guidance, or financing details.
Risk Factors
- Tafenoquine is not FDA-approved for babesiosis; trial failure or negative interim analysis would be highly dilutive to valuation.
- Company has a going-concern warning (substantial doubt about ability to continue) disclosed in prior 10-K, increasing financing risk before trial completion.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3301055 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | 8-K | $0.8759 | awaiting T+5 | — | $0.8700 (−0.67%) |
Oct 6, 2026 20d ago | Press Release | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Oct 6, 2026 20d ago | 8-K | $1.11 $0.9000 | ▼ −18.92% | ▼ −18.78% | $0.8700 (−21.62%) |
Aug 26, 2026 8w ago | EFFECT | $1.08 $0.9495 | ▲ +12.08% | ▲ +11.96% | $0.8700 (+19.44%) |
Aug 14, 2026 10w ago | Press Release | $1.20 $1.13 | ▲ +5.44% | ▲ +4.07% | $0.8700 (+27.20%) |
Jul 30, 2026 12w ago | Press Release | $1.25 $1.15 | ▲ +8.00% | ▲ +11.62% | $0.8700 (+30.40%) |
Jul 1, 2026 16w ago | Press Release | $1.75 $1.55 | ▼ −11.43% | ▼ −11.38% | $0.8700 (−50.29%) |
May 26, 2026 21w ago | Press Release | $1.50 $1.46 | ▼ −2.67% | ▼ −3.75% | $0.8700 (−42.00%) |
May 15, 2026 23w ago | Press Release | $1.39 $1.48 | ▼ −6.47% | ▼ −5.51% | $0.8700 (+37.41%) |
Mar 31, 2026 29w ago | Press Release | $1.75 $1.81 | ▲ +3.43% | ▼ −0.52% | $0.8700 (−50.29%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers